title: Serum anti-60S ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer.
abstract: OBJECTIVE
  Recently, we found the presence of anti-60S ribosomal protein L29 antibody (anti-RPL29) in human sera, inhibiting the proliferation of pancreatic cancer cells in vitro. We aimed to estimate the association of serum anti- RPL29 levels with clinical features in patients affected with unresectable pancreatic cancer.
  
  
  METHODS
  We retrospectively reviewed 105 patients with unresectable pancreatic cancer. Serum anti-RPL29 levels were measured by the indirect enzyme-linked immunosorbent assay. The cut-off was represented by the 95th percentile in 62 healthy volunteers.
  
  
  RESULTS
  Median survival time (MST) was 11.1 months in 49 patients showing serum anti-RPL29 level >cut-off and 7.4 months in 56 patients showing serum anti-RPL29 level ≤ cutoff. In locally advanced disease, MST was 17.9 months in 22 patients showing serum anti-RPL29 level >cut-off and 10.0 months in 19 patients showing serum anti-RPL29 level ≤ cutoff. In metastatic disease, MST was 8.7 months in 27 patients showing serum anti-RPL29 level >cut-off and 5.9 months in 37 patients showing serum anti-RPL29 level ≤ cut-off. In the multivariate Cox proportional hazard model, serum anti- RPL29 level >cut-off, abdominal or back pain, performance status, and metastatic disease were identified as independent prognostic factors.
  
  
  CONCLUSIONS
  Serum anti-RPL29 levels may be a novel candidate for a prognostic marker for unresectable pancreatic cancer.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Muro
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Miyake
authors.forename: Hironari
authors.initials: H
authors.lastname: Kato
authors.forename: Koichiro
authors.initials: K
authors.lastname: Tsutsumi
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000230:Adenocarcinoma / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001779:Blood Coagulation Factors / Q000276:immunology*; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000401:mortality; D011379:Prognosis; D016016:Proportional Hazards Models; D016601:RNA-Binding Proteins; D012189:Retrospective Studies; D012269:Ribosomal Proteins; D054683:Ribosome Subunits, Large, Eukaryotic / Q000276:immunology*; D016019:Survival Analysis
chemical_list: D000906:Antibodies; D014408:Biomarkers, Tumor; D001779:Blood Coagulation Factors; D016601:RNA-Binding Proteins; C104946:RPL29 protein, human; D012269:Ribosomal Proteins